The emergence of various new drugs and treatment strategies, such as next-generation proteasome inhibitors (Carfilzomib, Ixazomib), immunomodulatory drugs (Pomalidomide), CD38 antibodies (Daratumumab, Isatuximab), and the Elotuzumab monoclonal antibody, offers new hope for treating high-risk MM (HRMM) patients. Here, CD38 is linked to Miyoshi myopathy.